Literature DB >> 3013134

Immunogenicity of purified glycoprotein gB of herpes simplex virus.

Y Kino, T Eto, K Nishiyama, N Ohtomo, R Mori.   

Abstract

The efficacy of a herpes simplex virus (HSV) component vaccine consisting of viral glycoprotein gB was examined in a mouse system. Immunization of mice with HSV type 1 (HSV-1) gB emulsified in Freund's complete adjuvant or with HSV-1 gB adsorbed to aluminum gel was fully protective against subsequent challenge with HSV-1 or HSV type 2. Latent infection in the trigeminal ganglion was also prevented by immunization with gB.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3013134     DOI： 10.1007/bf01309880

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  26 in total

1.  Defective in vitro lymphoproliferative responses to herpes simplex virus in patients with frequently recurring herpes infections during the disease-free interval.

Authors:  H Kirchner; M Schwenteck; H Northoff; E Schöpf
Journal:  Clin Immunol Immunopathol       Date:  1978-11

2.  Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection.

Authors:  J E Oakes
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

3.  Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice.

Authors:  S Nagafuchi; H Oda; R Mori; T Taniguchi
Journal:  J Gen Virol       Date:  1979-09       Impact factor: 3.891

4.  Difference in age distribution of antibody to herpes simplex virus in Fukuoka, Manila and Busan.

Authors:  Y Hayashi; M Nagata; H Yoshizumi; R Mori; C V Navarro; H D Yang
Journal:  Jpn J Med Sci Biol       Date:  1984-02

5.  Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2.

Authors:  D Long; T J Madara; M Ponce de Leon; G H Cohen; P C Montgomery; R J Eisenberg
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

6.  Passive immunization of mice with monoclonal antibodies to glycoprotein gB of herpes simplex virus.

Authors:  Y Kino; T Eto; N Ohtomo; Y Hayashi; M Yamamoto; R Mori
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

7.  An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D.

Authors:  J H Weis; L W Enquist; J S Salstrom; R J Watson
Journal:  Nature       Date:  1983-03-03       Impact factor: 49.962

8.  The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.

Authors:  V C Carter; P A Schaffer; S S Tevethia
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

9.  Type-common and type-specific monoclonal antibody to herpes simplex virus type 1.

Authors:  L Pereira; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.

Authors:  R J Klein; E Buimovici-Klein; H Moser; R Moucha; J Hilfenhaus
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574
View more
  7 in total

1.  Expression of cell-associated and secreted forms of herpes simplex virus type 1 glycoprotein gB in mammalian cells.

Authors:  C Pachl; R L Burke; L L Stuve; L Sanchez-Pescador; G Van Nest; F Masiarz; D Dina
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

2.  Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.

Authors:  Tansi Khodai; Debbie Chappell; Clare Christy; Paul Cockle; Jim Eyles; Daisy Hammond; Katrina Gore; Michael J McCluskie; Dana M Evans; Susanne Lang; Peter T Loudon; Tim Townend; Paul Wright; Kate West; Helen Bright
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

3.  Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.

Authors:  M Bröker; K J Abel; R Köhler; J Hilfenhaus; E Amann
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

4.  Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.

Authors:  E M Cantin; R Eberle; J L Baldick; B Moss; D E Willey; A L Notkins; H Openshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.

Authors:  L A Morrison; D M Knipe
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  Zwitterionic detergent solubilisation of HSV-1 surface antigens.

Authors:  R Jennings; T Quasim; R M Sharrard; D Hockley; C W Potter
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

Review 7.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.